Rani Therapeutics Holdings Inc (RANI) USD0.0001 A

Sell:$1.30Buy:$1.41$0.01 (0.74%)

Prices delayed by at least 15 minutes
Sell:$1.30
Buy:$1.41
Change:$0.01 (0.74%)
Prices delayed by at least 15 minutes
Sell:$1.30
Buy:$1.41
Change:$0.01 (0.74%)
Prices delayed by at least 15 minutes

Company Information

About this company

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.

Key people

Mir Imran
Executive Chairman of the Board
Talat Imran
Chief Executive Officer, Director
Svai S. Sanford
Chief Financial Officer
Mir Hashim
Chief Scientific Officer
Eric Groen
General Counsel
Kate Mckinley
Chief Business Officer
Laureen Debuono
Lead Independent Director
Andrew Farquharson
Director
Dennis A. Ausiello
Independent Director
Jean-Luc Butel
Independent Director
Maulik Nanavaty
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US7530181004
  • Market cap
    $79.63m
  • Employees
    140
  • Shares in issue
    33.31m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.